SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,637.37 (-2.86%)
DOW   29,247.88 (-2.27%)
QQQ   269.09 (-3.81%)
AAPL   140.22 (-3.58%)
MSFT   234.37 (-5.03%)
META   133.37 (-4.10%)
GOOGL   98.62 (-2.76%)
AMZN   114.65 (-4.70%)
TSLA   223.94 (-5.96%)
NVDA   121.38 (-7.56%)
NIO   13.74 (-6.97%)
BABA   81.03 (-3.90%)
AMD   59.26 (-12.66%)
T   15.01 (-2.02%)
MU   53.06 (-2.86%)
CGC   2.83 (-24.53%)
F   12.15 (-1.70%)
GE   64.31 (-2.88%)
DIS   96.81 (-3.23%)
AMC   6.48 (-8.99%)
PYPL   90.19 (-4.48%)
PFE   42.16 (-2.16%)
NFLX   227.17 (-5.35%)
S&P 500   3,637.37 (-2.86%)
DOW   29,247.88 (-2.27%)
QQQ   269.09 (-3.81%)
AAPL   140.22 (-3.58%)
MSFT   234.37 (-5.03%)
META   133.37 (-4.10%)
GOOGL   98.62 (-2.76%)
AMZN   114.65 (-4.70%)
TSLA   223.94 (-5.96%)
NVDA   121.38 (-7.56%)
NIO   13.74 (-6.97%)
BABA   81.03 (-3.90%)
AMD   59.26 (-12.66%)
T   15.01 (-2.02%)
MU   53.06 (-2.86%)
CGC   2.83 (-24.53%)
F   12.15 (-1.70%)
GE   64.31 (-2.88%)
DIS   96.81 (-3.23%)
AMC   6.48 (-8.99%)
PYPL   90.19 (-4.48%)
PFE   42.16 (-2.16%)
NFLX   227.17 (-5.35%)
S&P 500   3,637.37 (-2.86%)
DOW   29,247.88 (-2.27%)
QQQ   269.09 (-3.81%)
AAPL   140.22 (-3.58%)
MSFT   234.37 (-5.03%)
META   133.37 (-4.10%)
GOOGL   98.62 (-2.76%)
AMZN   114.65 (-4.70%)
TSLA   223.94 (-5.96%)
NVDA   121.38 (-7.56%)
NIO   13.74 (-6.97%)
BABA   81.03 (-3.90%)
AMD   59.26 (-12.66%)
T   15.01 (-2.02%)
MU   53.06 (-2.86%)
CGC   2.83 (-24.53%)
F   12.15 (-1.70%)
GE   64.31 (-2.88%)
DIS   96.81 (-3.23%)
AMC   6.48 (-8.99%)
PYPL   90.19 (-4.48%)
PFE   42.16 (-2.16%)
NFLX   227.17 (-5.35%)
S&P 500   3,637.37 (-2.86%)
DOW   29,247.88 (-2.27%)
QQQ   269.09 (-3.81%)
AAPL   140.22 (-3.58%)
MSFT   234.37 (-5.03%)
META   133.37 (-4.10%)
GOOGL   98.62 (-2.76%)
AMZN   114.65 (-4.70%)
TSLA   223.94 (-5.96%)
NVDA   121.38 (-7.56%)
NIO   13.74 (-6.97%)
BABA   81.03 (-3.90%)
AMD   59.26 (-12.66%)
T   15.01 (-2.02%)
MU   53.06 (-2.86%)
CGC   2.83 (-24.53%)
F   12.15 (-1.70%)
GE   64.31 (-2.88%)
DIS   96.81 (-3.23%)
AMC   6.48 (-8.99%)
PYPL   90.19 (-4.48%)
PFE   42.16 (-2.16%)
NFLX   227.17 (-5.35%)
NASDAQ:RDUS

Radius Health - RDUS Stock Forecast, Price & News

$10.08
0.00 (0.00%)
(As of 09/16/2022)
Add
Compare
Today's Range
$10.08
▼
$10.08
50-Day Range
$10.07
▼
$10.22
52-Week Range
$4.97
▼
$23.00
Volume
4,802 shs
Average Volume
1.17 million shs
Market Capitalization
$480.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Radius Health MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
14.7% Downside
$8.60 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$40,401 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

1058th out of 1,075 stocks

Pharmaceutical Preparations Industry

529th out of 537 stocks

See Top Rated MarketRank™ Stocks Here
RDUS stock logo

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Stock News Headlines

October 6, 2022 | americanbankingnews.com
Radius Health (NASDAQ:RDUS) Coverage Initiated by Analysts at StockNews.com
September 28, 2022 | americanbankingnews.com
Radius Health (NASDAQ:RDUS) Research Coverage Started at StockNews.com
August 15, 2022 | finance.yahoo.com
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
August 11, 2022 | markets.businessinsider.com
FDA Accepts Menarini Group and Radius Health's Filing Under Priority Review For Breast Cancer Candidate
August 11, 2022 | finance.yahoo.com
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
July 28, 2022 | finance.yahoo.com
Mass. M&A activity picks up among life sciences firms
July 15, 2022 | seekingalpha.com
Golden Age Of Merger Arb: Radius
July 11, 2022 | finance.yahoo.com
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
July 8, 2022 | finance.yahoo.com
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
July 7, 2022 | finance.yahoo.com
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
July 7, 2022 | benzinga.com
Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
July 7, 2022 | barrons.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, RADA, GRRB, EPZM
July 7, 2022 | finance.yahoo.com
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
July 6, 2022 | benzinga.com
Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm
July 6, 2022 | apnews.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VMW, CMAX, RDUS, FSTX
July 6, 2022 | apnews.com
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
June 28, 2022 | markets.businessinsider.com
Short Volatility Alert: Radius Health, Inc.
June 28, 2022 | benzinga.com
Equity Alert - The M&A Class Action Firm Announces an Investigation of Radius Health, Inc. - RDUS
June 27, 2022 | apnews.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAK
June 25, 2022 | benzinga.com
RADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the Firm
June 24, 2022 | seekingalpha.com
Hot Stocks: KMX, BB rise on earnings; WOLF upgrade; RDUS slips after previous day's gains
June 24, 2022 | bizjournals.com
Equity firms to take Radius Health private for $890M
June 24, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Radius Health
June 23, 2022 | apnews.com
RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders
June 23, 2022 | marketwatch.com
Radius Health Shares Leap on Deal to Be Taken Private >RDUS
See More Headlines
Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Company Calendar

Last Earnings
8/09/2022
Today
10/07/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
CUSIP
N/A
CIK
1428522
Web
www.radiuspharm.com
Phone
(617) 551-4000
Fax
617-551-4701
Employees
293
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-14.7%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,180,000.00
Net Margins
-30.73%
Pretax Margin
-30.73%
Return on Equity
N/A
Return on Assets
-40.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.67
Quick Ratio
1.52

Sales & Book Value

Annual Sales
$229.97 million
Price / Sales
2.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.74) per share
Price / Book
-1.76

Miscellaneous

Outstanding Shares
47,620,000
Free Float
46,796,000
Market Cap
$480.01 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Mr. G. Kelly Martin (Age 63)
    CEO, Pres & Director
    Comp: $600.48k
  • Ms. Danielle Holtschlag (Age 44)
    VP of Sales & Head of U.S. Sales Channels
    Comp: $299.3k
  • Ms. Chhaya Shah (Age 58)
    Sr. VP & Chief Bus. Officer
    Comp: $631.62k
  • Dr. Stavros C. Manolagas
    Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr. (Age 90)
    DSc, M.D., Founder & Member of the Scientific Advisory Board
  • Dr. Michael Rosenblatt M.D. (Age 74)
    Founder, Board Observer & Member of Scientific Advisory Board
  • Dr. John A. Katzenellenbogen
    Founder & Member of the Scientific Advisory Board
  • Mr. Mark William Conley CPA (Age 60)
    VP, CFO, Principal Accounting Officer & Treasurer
  • Mr. Peter A. Schwartzman
    Head of Corp. Fin.
  • Ethan Holdaway
    Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RDUS Stock - Frequently Asked Questions

Should I buy or sell Radius Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings or view top-rated stocks.

What is Radius Health's stock price forecast for 2022?

5 equities research analysts have issued 12-month price objectives for Radius Health's shares. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.60 in the next twelve months. This suggests that the stock has a possible downside of 14.7%.
View analysts price targets for RDUS or view top-rated stocks among Wall Street analysts.

How have RDUS shares performed in 2022?

Radius Health's stock was trading at $6.92 on January 1st, 2022. Since then, RDUS shares have increased by 45.7% and is now trading at $10.08.
View the best growth stocks for 2022 here.

When is Radius Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RDUS earnings forecast.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) released its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.35. The biopharmaceutical company had revenue of $58.29 million for the quarter, compared to the consensus estimate of $67.95 million.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How do I buy shares of Radius Health?

Shares of RDUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $10.08.

How much money does Radius Health make?

Radius Health (NASDAQ:RDUS) has a market capitalization of $480.01 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Radius Health have?

The company employs 293 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.